Relmada Therapeutics to Discuss Fourth Quarter Financials
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a pioneering biotechnology firm, is set to host an important conference call and webcast to share their fourth-quarter financial results and recent advancements in their programs. This event will take place on a day that is significant for the company as they reflect on their progress and outline future directions.
Conference Call and Webcast Details
The conference call is scheduled for a Thursday afternoon, an ideal time for investors and stakeholders to join and hear directly from the company's leadership. The call is expected to start promptly at 4:30 PM Eastern Time.
How to Participate
For those who wish to dial in, there are specific numbers available. Participants in the United States can call 1-877-407-0792, while international attendees can reach the conference at 1-201-689-8263. The conference ID for this event is 13751458, ensuring your entry into the call.
Webcast Access
For convenient access to the discussion, a webcast will also be available. Participants can easily join online to hear the live presentation and reflect on the opportunities presented by the company.
Webcast Replay Availability
For those unable to attend the live discussion, a replay of the webcast will be accessible afterward in the Investors section of Relmada's official website. This feature allows stakeholders to stay updated on the company's performance and strategic plans.
Company Overview: Relmada Therapeutics
Relmada Therapeutics is dedicated to transforming the landscape of treatment options for patients. As a clinical-stage biotech organization, they focus on developing groundbreaking therapies aimed at providing significant clinical benefits to those in need.
Innovative Programs Under Development
One of the company's lead investigational programs, NDV-01, is currently in a Phase 2 study targeting High-Grade Non-Muscle Invasive Bladder Cancer. This program represents a crucial step in finding effective treatments for patients suffering from this condition, showcasing Relmada's commitment to innovation.
Advancements in Compulsion-Related Disorders
In addition, preparations are in progress to advance Relmada’s investigational program, sepranolone. This program is ready to enter Phase 2b trials and focuses on compulsion-related disorders, including Tourette’s Syndrome. These efforts illustrate the company's proactive approach in addressing various challenging health issues.
Stay Informed with Relmada Therapeutics
The company encourages everyone to stay informed about their progress by regularly visiting their website and accessing investor resources. This way, stakeholders can keep abreast of new developments and planned releases that may impact their investments.
Contacting Relmada Therapeutics
If you have any inquiries, they have dedicated contacts for investor relations and media inquiries. Brian Ritchie from LifeSci Advisors is the primary contact for investor-related questions, reachable via email. Additionally, media inquiries can be directed to the corporate communications team via another dedicated email.
Frequently Asked Questions
What time is the fourth-quarter financial results conference call?
The conference call will take place at 4:30 PM ET on Thursday.
How can I access the webcast of the conference call?
You can access the webcast through the official Relmada Therapeutics website.
What is Relmada Therapeutics focusing on in their programs?
Relmada focuses on innovative therapies for conditions such as High-Grade Non-Muscle Invasive Bladder Cancer and compulsion-related disorders.
Who can I contact for investor-related inquiries?
Brian Ritchie at LifeSci Advisors is the contact for investor inquiries.
Where can I find more information about Relmada Therapeutics?
More information can be found on Relmada Therapeutics' official website, where updates and resources are regularly posted.
